Jonathan Lim Biography and Net Worth

Chairman, CEO and Co-founder of Erasca

Jonathan is Chairman and CEO of Erasca, which he co-founded in July 2018 with a mission to erase cancer. He is a physician-turned-venturepreneur at City Hill and ARCH Venture who founds, funds and leads mission-driven for-profit and non-profit ventures. He has served as Chairman and/or CEO and founding investor of six biotechnology companies that have collectively achieved global regulatory approval and launch of seven therapeutic products in oncology, immunology and drug delivery, benefitting thousands of patients worldwide, while generating approximately $10 billion of shareholder value. Jonathan has pioneered transformative advancements in drug delivery and precision oncology.

In drug delivery, he designed and executed landmark deals for Halozyme’s ENHANZE^® drug delivery technology with Roche/Genentech and Baxter that formed the foundational business model and template for the company’s ten global alliances and five approved ENHANZE products that have enabled Halozyme to turn EBITDA positive and guide to $1 billion in royalty revenue in 2027. In precision oncology, Jonathan led Ignyta’s trailblazing pursuit of a global tissue agnostic label to transform cancer treatment with ROZLYTREK^® (entrectinib) that, in the process of securing global regulatory approvals, became the first drug in biopharmaceutical history to achieve the unprecedented triple crown of breakthrough designations with BTD (FDA), PRIME (EMA) and Sakigake (PMDA). He led the strategic process that successfully resulted in the acquisition of Ignyta to become a key personalized healthcare pillar for Roche/Genentech, the leading precision oncology company in the world. He is continuing to pursue new frontiers of precision oncology at Erasca.

What is Jonathan E. Lim's net worth?: The estimated net worth of Jonathan E. Lim is at least $41.15 million as of December 5th, 2023. Mr. Lim owns 12,899,360 shares of Erasca stock worth more than $41,148,958 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Lim may own. Additionally, Mr. Lim receives a salary of $987,700.00 as Chairman, CEO and Co-founder at Erasca. Learn More about Jonathan E. Lim's net worth.
How old is Jonathan E. Lim?: Mr. Lim is currently 52 years old. There are 6 older executives and no younger executives at Erasca. Learn More on Jonathan E. Lim's age.
What is Jonathan E. Lim's salary?: As the Chairman, CEO and Co-founder of Erasca, Inc., Mr. Lim earns $987,700.00 per year. Learn More on Jonathan E. Lim's salary.
How do I contact Jonathan E. Lim?: The corporate mailing address for Mr. Lim and other Erasca executives is , , . Erasca can also be reached via phone at 858-465-6511 and via email at [email protected]. Learn More on Jonathan E. Lim's contact information.
Has Jonathan E. Lim been buying or selling shares of Erasca?: Jonathan E. Lim has not been actively trading shares of Erasca within the last three months. Most recently, on Tuesday, December 5th, Jonathan E. Lim bought 721,850 shares of Erasca stock. The stock was acquired at an average cost of $1.69 per share, with a total value of $1,219,926.50. Following the completion of the transaction, the chief executive officer now directly owns 12,899,360 shares of the company's stock, valued at $21,799,918.40. Learn More on Jonathan E. Lim's trading history.
Who are Erasca's active insiders?: Erasca's insider roster includes Alexander Casdin (Director), Valerie Harding (Director), and Jonathan Lim (Chairman, CEO and Co-founder). Learn More on Erasca's active insiders.

Jonathan E. Lim Insider Trading History at Erasca

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2023	Buy	721,850	$1.69	$1,219,926.50	12,899,360
10/5/2023	Buy	1,000,000	$2.03	$2,030,000.00	19,456,216
6/8/2023	Buy	100,000	$2.75	$275,000.00	18,396,216
3/28/2023	Buy	100,000	$2.84	$284,000.00	18,296,216
1/10/2023	Buy	60,000	$3.86	$231,600.00	20,256,222
12/14/2022	Buy	40,000	$4.99	$199,600.00	20,196,222

Jonathan E. Lim Buying and Selling Activity at Erasca

Erasca Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Today's Range

Now: $3.19

$3.17

$3.36

50 Day Range

MA: $2.54

$2.08

$3.29

2 Week Range

Now: $3.19

$1.01

$3.38

Volume

3,227,137 shs

Average Volume

1,804,237 shs

Market Capitalization

$905.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Jonathan Lim Biography and Net Worth

What is Jonathan E. Lim's net worth?

How old is Jonathan E. Lim?

What is Jonathan E. Lim's salary?

How do I contact Jonathan E. Lim?

Has Jonathan E. Lim been buying or selling shares of Erasca?

Who are Erasca's active insiders?